Ignite Creation Date:
2024-07-17 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06500624
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-07-08
Brief Title:
Comparative Efficacy of Escitalopram Monotherapy and Escitalopram in Adjuvant With Pizotifen in Depressive Disorder
Sponsor:
Riphah International University
Organization:
Riphah International University
Study Overview
Official Title:
Comparative Efficacy of Escitalopram Monotherapy and Escitalopram in Adjuvant With Pizotifen in Depressive Disorder
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare the efficacy of escitalopram monotherapy and combination with pizotifen in patients of major depressive disorderMDDThe levels of depressive symptoms as measured by the Patient Health Questionnaire PHQ-9 at base level and during follow-up
Detailed Description:
This is an open-label study assessing the comparative efficacy of escitalopram monotherapy and combination with pizotifen in patients of major depressive disorder efficacy of antidepressants in combination therapy The plan is to enroll 84 patients with depression based on the Patient Health Questionnaire PHQ-9 score of 9 and above is a valid and reliable Structured Clinical Interview The investigators will collect data from the enrolled patient populations The participants will be able to receive their results on request upon completion of the study The investigators hypothesize that depressive symptoms can be improved by the addition of the above-mentioned drug with antidepressant medication
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None